131 related articles for article (PubMed ID: 28940490)
21. A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice.
Pereira VB; Melo AT; Assis-Júnior EM; Wong DV; Brito GA; Almeida PR; Ribeiro RA; Lima-Júnior RC
Cancer Chemother Pharmacol; 2016 Feb; 77(2):323-32. PubMed ID: 26666645
[TBL] [Abstract][Full Text] [Related]
22. The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
Wong DV; Lima-Júnior RC; Carvalho CB; Borges VF; Wanderley CW; Bem AX; Leite CA; Teixeira MA; Batista GL; Silva RL; Cunha TM; Brito GA; Almeida PR; Cunha FQ; Ribeiro RA
PLoS One; 2015; 10(10):e0139985. PubMed ID: 26440613
[TBL] [Abstract][Full Text] [Related]
23. Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice.
Lima-Júnior RC; Freitas HC; Wong DV; Wanderley CW; Nunes LG; Leite LL; Miranda SP; Souza MH; Brito GA; Magalhães PJ; Teixeira MM; Cunha FQ; Ribeiro RA
Br J Pharmacol; 2014 May; 171(9):2335-50. PubMed ID: 24428790
[TBL] [Abstract][Full Text] [Related]
24. Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study.
Al-Dasooqi N; Bowen J; Bennett C; Finnie J; Keefe D; Gibson R
Support Care Cancer; 2017 Feb; 25(2):391-398. PubMed ID: 27650103
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
Ribeiro RA; Wanderley CW; Wong DV; Mota JM; Leite CA; Souza MH; Cunha FQ; Lima-Júnior RC
Cancer Chemother Pharmacol; 2016 Nov; 78(5):881-893. PubMed ID: 27590709
[TBL] [Abstract][Full Text] [Related]
26. Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis.
Bastos RW; Pedroso SH; Vieira AT; Moreira LM; França CS; Cartelle CT; Arantes RM; Generoso SV; Cardoso VN; Neves MJ; Nicoli JR; Martins FS
Benef Microbes; 2016 Sep; 7(4):549-57. PubMed ID: 27133563
[TBL] [Abstract][Full Text] [Related]
27. Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium.
Shinohara H; Killion JJ; Bucana CD; Yano S; Fidler IJ
Clin Cancer Res; 1999 Aug; 5(8):2148-56. PubMed ID: 10473099
[TBL] [Abstract][Full Text] [Related]
28. Curcumin protects heart tissue against irinotecan-induced damage in terms of cytokine level alterations, oxidative stress, and histological damage in rats.
Ciftci O; Turkmen NB; Taslıdere A
Naunyn Schmiedebergs Arch Pharmacol; 2018 Aug; 391(8):783-791. PubMed ID: 29721577
[TBL] [Abstract][Full Text] [Related]
29. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?
Logan RM; Stringer AM; Bowen JM; Gibson RJ; Sonis ST; Keefe DM
Cancer Chemother Pharmacol; 2009 Jan; 63(2):239-51. PubMed ID: 18351341
[TBL] [Abstract][Full Text] [Related]
30. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
Cao S; Black JD; Troutt AB; Rustum YM
Cancer Res; 1998 Aug; 58(15):3270-4. PubMed ID: 9699654
[TBL] [Abstract][Full Text] [Related]
31. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.
Sezer A; Usta U; Cicin I
Med Oncol; 2009; 26(3):350-7. PubMed ID: 19067257
[TBL] [Abstract][Full Text] [Related]
32. Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.
Fittkau M; Voigt W; Holzhausen HJ; Schmoll HJ
J Cancer Res Clin Oncol; 2004 Jul; 130(7):388-94. PubMed ID: 15160289
[TBL] [Abstract][Full Text] [Related]
33. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity.
Zhao J; Huang L; Belmar N; Buelow R; Fong T
Clin Cancer Res; 2004 Apr; 10(8):2851-9. PubMed ID: 15102694
[TBL] [Abstract][Full Text] [Related]
34. Role of regulatory T cells in irinotecan-induced intestinal mucositis.
Fernandes C; Wanderley CWS; Silva CMS; Muniz HA; Teixeira MA; Souza NRP; Cândido AGF; Falcão RB; Souza MHLP; Almeida PRC; Câmara LMC; Lima-Júnior RCP
Eur J Pharm Sci; 2018 Mar; 115():158-166. PubMed ID: 29307857
[TBL] [Abstract][Full Text] [Related]
35. Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice.
Justino PF; Melo LF; Nogueira AF; Costa JV; Silva LM; Santos CM; Mendes WO; Costa MR; Franco AX; Lima AA; Ribeiro RA; Souza MH; Soares PM
Br J Nutr; 2014 May; 111(9):1611-21. PubMed ID: 24503021
[TBL] [Abstract][Full Text] [Related]
36. Irinotecan changes gene expression in the small intestine of the rat with breast cancer.
Bowen JM; Gibson RJ; Cummins AG; Tyskin A; Keefe DM
Cancer Chemother Pharmacol; 2007 Feb; 59(3):337-48. PubMed ID: 16799812
[TBL] [Abstract][Full Text] [Related]
37. Intestinal microflora and digestive toxicity of irinotecan in mice.
Brandi G; Dabard J; Raibaud P; Di Battista M; Bridonneau C; Pisi AM; Morselli Labate AM; Pantaleo MA; De Vivo A; Biasco G
Clin Cancer Res; 2006 Feb; 12(4):1299-307. PubMed ID: 16489087
[TBL] [Abstract][Full Text] [Related]
38. Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-induced mucositis through IL-1β and IL-18 in mice.
Arifa RD; Madeira MF; de Paula TP; Lima RL; Tavares LD; Menezes-Garcia Z; Fagundes CT; Rachid MA; Ryffel B; Zamboni DS; Teixeira MM; Souza DG
Am J Pathol; 2014 Jul; 184(7):2023-34. PubMed ID: 24952429
[TBL] [Abstract][Full Text] [Related]
39. Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis.
Fakiha K; Coller JK; Logan RM; Gibson RJ; Bowen JM
Support Care Cancer; 2019 Jun; 27(6):2313-2320. PubMed ID: 30350190
[TBL] [Abstract][Full Text] [Related]
40. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
